DLCA definition
Examples of DLCA in a sentence
OF ALABAMA ("DLCA"), an Alabama corporation and wholly-owned subsidiary of DLC, ADVOCAT DISTRIBUTION SERVICES, INC.
Merger Sub II shall continue as the surviving entity in the Second Merger (the “Surviving Entity”) and shall succeed to and assume all the rights and obligations of Company and Surviving Entity I in accordance with the DGCL and the DLCA.
Immediately following the Effective Time of the First Merger (as defined in Section 1.2), upon the terms and subject to the conditions set forth in this Agreement and the applicable provisions of the DGCL and the DLCA, Surviving Entity I will be merged with and into Merger Sub II (the “Second Merger” and, together with the First Merger, the “Transaction”), and the separate existence of Surviving Entity I shall cease.
The effect of the Transaction shall be as provided in this Agreement and the applicable provisions of the DGCL and the DLCA.
As soon as practicable after the Effective Time, upon the terms and subject to the conditions set forth in this Agreement and the applicable provisions of the DGCL and the DLCA, Surviving Entity I will be merged with and into Merger Sub II, and the separate existence of Surviving Entity I shall cease.
Idenix’s right to audit Novartis in respect of LdT Products shall be limited to verifying the basis and accuracy of reporting and payments made, if any, by Novartis to Idenix under Sections 5.11, 8.6(a)(i) and 8.8A of the DLCA or under this Section 3 of this Exhibit D.
The terms of Section 8.10 of the DLCA shall apply to any audit conducted pursuant to this Section.
The First Closing shall have occurred and the Merger and Second Merger shall have become effective under the DGCL and DLCA.
The provisions of this Section 4(d) shall be subject to the provisions of Section 11.5 of the DLCA, which shall govern as to both costs and procedures in the event of infringement actions relating to an LdT Product brought by a Third Party against Novartis and/or Idenix in which the Third Party claim[s], if true, would constitute a breach of representation, warranty or obligation covered by Section 11.5 of the DLCA.
The Parties agree and acknowledge that such license was originally granted to Novartis pursuant to Amendment No. 4 of the DLCA, and that such license is merely an extension of the license granted to Novartis pursuant to Amendment No. 4 of the DLCA.